Mindset is pleased to announce the allowance of U.S. claims for it's vaccine patent

The vaccine was invented by scientists at New York University School of Medicine, and is exclusively licensed to Mindset for development.  In relevant animal models of Alzheimer’s disease, the Mindset vaccine was shown to inhibit the deposition of toxic amyloid fibrils and to improve cognition. Importantly, Mindset’s technology potentially addresses several major safety concerns for developing a vaccine to beta-amyloid.  See accompanying Press Release.

Dr. Daniel Chain,  CEO, is presenting at the 17th Annual Conference of the Rural Doctors of Ireland

Dr. Daniel Chain, CEO, is presenting at the 17th Annual Conference of the Rural Doctors of Ireland, 16th November 2002, sponsored by Astra Zeneca, Merk, Lundbeck and Servier: Dr. Chain will speak on "Challenges in Developing an Alzheimer's Vaccine". The conference will take place at Dromoland Castle in County Clare.

Dr. Daniel Chain, CEO, is presenting at the 8th International Partnering Conference, Bio-Europe, on 11th November in Stuttgart, Germany.

Dr. Chain is participating in the conference as a member of a panel entitled: "Alzheimer's Disease - Where are the Drugs"? Dr. Chain will speak about the founding principals behind, Mindset, and the company's efforts to develop and commercialize a variety of Alzheimer's therapeutics. His presentation will outline the basis of Mindset' s business model and product pipeline.

Mindset was featured in Venture Reporter Top 100 Venture-Backed Companies, 2002

Mindset is pleased to announce that Shalom Allenstein,  B.Sc (Econ), ACA, CPA, has joined the company as Chief Financial Officer.  Mr. Allenstein has more than 15 years experience in finance management and has held senior management positions with several successful companies.  Most recently, Mr. Allenstein was the CFO at Proficiency Ltd, a Jerusalem-based company with 95 employees. Previously, Mr. Allenstein was one of the original employees at Cellcom, the leading Israeli cellular telephone company, where he was the Financial Comptroller responsible for the internal control and financial reporting as the company grew from a startup to over $1 billion in turnover in 5 years. Mr. Allenstein is experienced in US and Israeli corporate accounting. He obtained his degree in economics, specializing in computing from the London School of Economics in 1980.
"We welcome Mr. Allenstein as a valuable addition to our team. We are confident in Mr. Allenstein's capabilities to lead the financial management of this fast evolving biopharmaceutical company" said Dr. Daniel Chain, Mindset's President and Chief Executive Officer. "The company aims to have its lead product, OXIGON®, in human clinical trials early 2003”, added Dr. Chain.

For the full press release press here

MindGenix Inc., a wholly-owned subsidiary of Mindset BioPharmaceuticals (USA) Inc., will participate in the 32nd Annual Meeting of the Society for Neuroscience, which will take place in Orlando, Florida

MindGenix' Director of World-Wide Marketing, Dr. Irene Zeitoun, will present the unique and proprietary double transgenic mouse model for Alzheimer's disease in Booth 1544.

For scheduling a meeting with the company's representative, please click here: izeitoun@mindgenix.com

The Society for Neuroscience Meeting is one of the largest meeting in the field, bringing together 25,000-30,000 participants each year, including academic scientists and leading biotechnology companies

Mindset and New York University Collaborate on Novel Vaccine Technology for Alzheimer’s Disease

Mindset BioPharmaceuticals (USA) Inc. and New York University School of Medicine (NYUSM) announced today that they have signed an agreement through which Mindset becomes the worldwide exclusive licensee of a breakthrough vaccine technology for the treatment of Alzheimer’s disease. The first promising results obtained from transgenic animal studies at NYUSM were published last year by the prestigious American Journal of Pathology.  Scientists at Mindset, led by Dr. Cheryl Fitzer Attas, have discovered that the vaccine is also less likely to cause an autoimmune response in patients. Many opinion leaders attribute a so-called T-cell mediated autoimmune response to the incidence of brain inflammation in a recent Alzheimer’s vaccine trial.

For the full press release press here

Mindset's Executive VP and Chief Medical Officer will serve as co-moderator with Professor Ephraim Katzir at the Prion Conference

Dr. Paul Bendheim, Mindset's Executive Vice President and Chief Medical Officer will serve as co-moderator with Professor Ephraim Katzir of the Weizmann Institute of Science at the Prion Conference Sponsored by the Adams Super Center for Brain Studies, Tel Aviv University and The Tel Aviv Sourasky Medical Center (Ichilov), Tel Aviv. The conference will be held at the Tel Aviv Sourasky Medical Center in Tel Aviv on Wednesday, July 17th, 2002.
 
Prion diseases of humans and animals share certain features with Alzheimer's disease, most notably the accumulation of an amyloid protein in the brain and significant oxidative damage. Previously, Dr. Bendheim and his research colleagues made important contributions to our current understanding of the unique pathogenetic mechanisms of prion diseases.

U.S. Patent Reinforces Mindset’s Leadership in Alzheimer’s Disease Drug Discovery

Mindset BioPharmaceuticals (USA) Inc., announced today that New York University School of Medicine and the University of South Alabama have been issued a U.S. patent relating to OXIGON®, the Company's industry-leading product for the treatment of Alzheimer’s disease. The patent, issued May 28, 2002 as US 6,395,768, covers the use of indole-3-propionic acid compounds to inhibit the deposition of toxic amyloid fibrils that lead to Alzheimer’s disease as well as prevent damage from oxidative stress. Mindset is the worldwide exclusive licensee of this platform patent.

For the full press release press here.

MindGenix Inc., a wholly-owned subsidiary of Mindset BioPharmaceuticals (USA) Inc., will participate in the 8th International Conference on Alzheimer's Disease and Related Disorders, which will take place in Stockholm, Sweden.

MindGenix' Director of Marketing, Dr. Irene Zeitoun, will present the unique and proprietary double transgenic mouse model for Alzheimer's disease in Booth A08:30.

For scheduling a meeting with the company's representative, please click here: izeitoun@mindset.co.il or mice@mindset.co.il.

The International Conference on Alzheimer's Disease and Related Disorders is an event occurring once every two years, bringing together academic scientists and leading biotechnology companies.

Mindset’s Director of Biological Research to present at AD conference

Dr. Cheryl Fitzer-Attas, Mindset’s Director of Biological Research, will present at The Ninth Tel-Aviv University Alzheimer’s Disease Conference. The conference will be held in Tel-Aviv, Israel, on June 6-7, 2002. Dr. Fitzer-Attas’ lecture is entitled ‘Safer Immunotherapies for AD’. For more information visit http://www.brain.tau.ac.il/

Mindset's Executive VP and Chief Medical Officer to present at Anti-Ageing Conference

Mindset’s Executive Vice President and Chief Medical Officer, Dr. Paul Bendheim, has been invited to present at SMI’s conference on Anti-Ageing Therapies. The conference will take place in London, The Hatton, on October 23-24. Dr. Bendheim’s presentation is titled ‘OXIGON: Dual Mechanism Approach to the Treatment of Alzheimer’s Disease - Targeting the beta-Amyloid Cascade in Alzheimer’s Disease'. For more information visit www.smi-online.co.uk/conferences/default.asp

Financial Times' favorable review of Mindset

The Financial Times published an in-depth favorable review of Mindset's strategy for developing a treatment for Alzheimer's disease. The review includes an analysis of Mindset's revenue generating drug discovery technology, a double transgenic model. For the full article press here.

Mindset's CEO to present at Bio-Tech Israel 2002

Dr. Daniel Chain, Mindset's CEO, has been invited to give a presentation in the Bio-Tech Israel 2002 conference. The lecture is titled "Accelerating and optimizing lead selection in Alzheimer's disease and cognitive impairment through a unique transgenic mouse model". The conference, which will take place in Tel-Aviv on March 20-21, brings together Israel's leading biotech companies and scientists. For more information: http://www.kenes.com/biotech/scientific.htm

Mindset's CEO appointed member of Bio-Tech Israel 2002 scientific committee

Mindset's CEO, Dr. Daniel Chain, has been appointed as a member of the scientific committee of Bio-Tech Israel 2002. The conference, which will take place in Tel-Aviv, Israel, on March 20-21, brings together Israel's leading biotechnology companies and scientists. For more information: http://www.kenes.com/biotech/

Mindset BioPharmaceuticals (USA) Inc. secures $15 million investment

Mindset BioPharmaceuticals (USA) Inc. secures a $15 million investment from MPM Capital and Clal Biotechnology Industries.

MPM Capital L.P., one of the largest asset management firms dedicated to the life sciences sector, and Clal Biotechnology Industries Ltd., Israel’s leading investor in life sciences, have signed final agreements to invest in Mindset BioPharmaceuticals Inc.MPM and CBI have acted as co-lead investors in this round of financing and shall invest $15 million, in two tranches, in the Jerusalem-based (Delaware registered) company.

For more information: Press Release

Mindset Biopharmaceuticals (USA) signs service agreement with Lundbeck

Mindset Biopharmaceuticals (USA) Inc. signs a service agreement with Lundbeck for testing Lundbeck's drug candidate in Mindset's double transgenic mouse model of Alzheimer's disease and cognitive impairment. This model enables rapid screening of multiple drug candidates. Mindset, which is the only company licensed to offer 3rd-party testing in the double transgenic (APP/PS1) mouse model, provides state-of-the-art services including, validated biochemical tests, high through-put neuropathology and behavioral testing, to accelerate and enhance the pharmaceutical lead selection process.

For more information: Press Release